Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions

New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness

Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their

MedCognetics and Laurel Bridge unite to revolutionize breast cancer screening with secure AI workflow

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test

Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks

Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery

New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,